Company intelligence / Profile preview

MGB Biopharma

Edinburgh, Scotland, United Kingdommgb-biopharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase IIa clinical proof of concept study for lead candidate MGB-BP-3 in CDAD patients with 100% efficacy in initial and sustained cure, demonstrating potential superiority over current standard of care

Therapeutic areas: Infectious Diseases
Modalities: Small molecules, specifically Minor Groove Binder (MGB) compounds
Industry: Biotech

Drug pipeline

2 assets

zinc tetra-ascorbo-camphorate

1 more asset in the full pipeline.

Request access →

Partnerships

University of Strathclyde (research collaboration)

Beyond the preview

Go deeper on MGB Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGB Biopharma.

Explore the full profile